Listen to part III of our #ACR20 Day 3 recap. Follow the link below or find us on Apple podcasts. https://t.co/sTxhkccumn https://t.co/OQFBE575P8

• https://bit.ly/3pai77a

Abst#1717 confirms that early start of csDMARDs as 1st line tx & keeping ts/bDMARD as 2nd line tx (or more) is associated w/ a favorable outcome at 10 yrs in the ESPOIR cohort (a French multi-center cohort that followed patients w/ early RA). #ACR20 @RheumNow https://t.co/bzZiShCF97

This - very cool. Not as impressive as the implanted vagal stimulation pilot data, but once a day and well tolerated. Very early days but enticing, we will see! #ACR20 ABST1995 @RheumNow https://t.co/QZ8npob2H9 https://t.co/fRlFwIHqky

• https://twitter.com/RichardPAConway/status/1325821699053383683

Wonder if you can predict development of clinical RA in those at risk either w/ a - +RF or +CCP - Relevant sxs w/ or w/o abs - 1st deg relatives do RA pts? Abst#1722 shows patterns of pain or degree of jt swelling from SPARRA Qnairre can do so. #ACR20 @RheumNow https://t.co/bQ4ZmSYhBe

Dr. Khanna NOVESA study #ACR20 Abst#L09. Autotaxin inhibitor ZIRI in early dcSSc. 21 pts ziri vs 12 PBO. mRSS at Wk24 mean difference -2.8. Ziri well-tolerated. Would be great for new drug for early SSc skin. @RheumNow. https://t.co/qpvLFsAe0x

FAST trial: allopurinol vs febuxostat on safety (for gout pts on allopurinol, with ≥1 CV RF, TTT dosing) febuxostat non-inferior for CV events Well, that's a relief. gout flare similar, good follow-up, colchicine did not influence out in Lancet today? #ACR20 ABSTL08 @RheumNow https://t.co/5LeXV5mgu9

RITAZAREM trial long-term follow-up -RTX vs AZA after RTX-induced remission in ANCA #vasculitis -RTX superior to AZA to prevent relapse -Relapse common regardless of therapy; high-dose RTX not effective beyond treatment period Abs#2052 #ACR20 @RheumNow https://t.co/bW7IaMnVCG

• Extended Follow-Up of Patients Recruited to a Randomized, Controlled Trial of R…

Physicians must perceive the patient as a person rather than a carrier of a disease disease - Eric Cassell. Check out this book, and other insights from @LCalabreseDO on patient/provider discordance #empathy #cleclinicrheum @HealioRheum @RheumNow https://t.co/f5jnUS701X

#ACR20 @RheumNow https://t.co/0Kfe3Zforl

• https://twitter.com/drtinamahajan/status/1325844984470310913

@SSNaushon MTX remains backbone of therapy given low cost, safety profile, and long experience with it. Majority of pts do well on MTX and do not require TNFi @Rheumnow.

Interesting Swedish abstract 1997 at #ACR20. Adjuvant #herpeszoster vaccine (Shingrix) not effective for 25% of JAKi-treated RA pts (n=40) for antibody response (T cell response usually worse, not reported). Is better than nothing good enough? Maybe we need to hold JAKi briefly?

L06: Mavrilimumab in #GCA ⭐️Efficacy and safety of MAV maintaining sustained remission 26w new and relapsing/ref #GCA Flare risk ➡️ 62% risk ⬇️ of flare w/ MAV Sustained remission➡️ 33% ⬆️ in MAV No diff in new or relapsing/ref pts, No diff in AE #ACR20 #ACRambassador

Fantastic session about the 2020 guidelines for management of RA! Soon to be published. One major difference from 2015 guidelines ➡️ Conditional recommendation to choose a Biologic over Triple Therapy in MTX-inadequate responders (Discussion about patient preference is key!) https://t.co/s016piIN7Q

• https://twitter.com/UNMC_Rheum/status/1325840359411343362

SLR comparing the 4-dose ANCA #vasculitis (AAV) rituximab regimen (widely used in RCTs) to 2-dose #rheumatoidarthritis RTX regimen (common in clinical practice), to induce AAV remission, finds no difference in efficacy or safety. Abs#2048 #ACR20 @RheumNow https://t.co/WBaWN9d8vs

• Comparison of Two Rituximab Regimens for Induction of Remission in Antineutroph…

.@LCalabreseDO from @ClevelandClinic is discussing the science of #empathy in #rheumatology at #ACR20. How important is empathy in your doctor-patient relationship? https://t.co/xIdPWmc7UV